GRI:NSD-GRI Bio Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.77

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.07M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 84.94B
ARGX argenx NV ADR

N/A

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.66B
BGNE BeiGene Ltd

N/A

USD 20.24B
UTHR United Therapeutics Corporatio..

N/A

USD 16.18B
MRNA Moderna Inc

N/A

USD 16.10B
RPRX Royalty Pharma Plc

N/A

USD 15.27B
SMMT Summit Therapeutics PLC

N/A

USD 13.67B
INCY Incyte Corporation

N/A

USD 13.52B

ETFs Containing GRI

UKPH:XETRA iShares UK Property UCITS.. 3.23 % 0.00 %

N/A

N/A
IUKP:SW iShares UK Property UCITS.. 3.18 % 0.00 %

N/A

USD 0.57B
UKRE:LSE iShares MSCI Target UK Re.. 2.54 % 0.00 %

N/A

USD 0.12B
IUKP:LSE iShares UK Property UCITS 0.00 % 0.00 %

N/A

USD 0.58B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -97.80% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.80% 2% F 1% F
Trailing 12 Months  
Capital Gain -97.54% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.54% 3% F 2% F
Trailing 5 Years  
Capital Gain -100.00% N/A F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -100.00% N/A F N/A F
Average Annual (5 Year Horizon)  
Capital Gain -34.46% 8% B- 5% F
Dividend Return -34.46% 8% B- 5% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 46.42% 67% D+ 41% F
Risk Adjusted Return -74.24% 13% F 8% B-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.